TG4050
TG4050 is an individualized therapeutic vaccine
A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate.
- Bespoke therapeutic vaccine
- Phase I
- Ovarian cancer; HPV-negative head & neck cancers
- myvac® platform
- Mechanism of action
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor.
Collaboration agreements
Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.
- June 3, 2024 - Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
- April 9, 2024 - Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- March 6, 2024 - Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
Discover myvac®
Clinical trials
| Indication | Phase | |
|---|---|---|
| Ovarian cancer – after first-line surgery and chemotherapy | Phase I | More information |
| HPV-negative head and neck cancers – after surgery and adjuvant therapy | Phase I | More information |
- Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
A. Lalanne, et al.
AACR 2024
Abstract available on the AACR website – Download the poster
Poster Presentation - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
C. Ottensmeier, et al.
ASCO 2023
Abstract available on the ASCO website – Download the abstract and the poster
Poster Presentation - Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.
AACR 2023
Download the poster here
Poster Presentation
